Moreover, transfer of Il-1α−/− BMDMs resulted in the development of splenomegaly (see Fig. S7 in the supplemental material) and an increase in bacterial burden in the spleens of Cl2MBP-treated WT mice (Fig. 6E), which correlated with a decrease in IL-1α serum concentrations without affecting IL-1β serum levels (Fig. 6F and G). Here, IL1B is linked to Splenomegaly.